Investors should monitor enrollment progress in the Phase 3 EMBARQ trial and upcoming interim or topline results, which could serve as major catalysts. The retreatment data de-risk development by supporting flexible dosing, potentially improving compliance and commercial adoption.
Price Chart
Executive Summary
Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU and SD, showing that retreatment leads to rapid and high rates of complete response, supporting the potential for intermittent, real-world treatment. The data reinforce the drug's durable efficacy and favorable safety profile, with 62% (ColdU) and 60% (SD) achieving complete response upon retreatment. A global Phase 3 trial is ongoing.
Key Facts
- Barzolvolimab retreatment achieved 62% complete response in ColdU and 60% in SD at Week 20 of the OLE, consistent with initial treatment efficacy.
- Among patients who achieved complete response initially, 82% (ColdU) and 86% (SD) achieved it again upon retreatment.
- Rapid improvement in urticaria control and symptom thresholds observed upon retreatment.
- Barzolvolimab targets mast cells via KIT receptor inhibition, a novel mechanism for chronic inducible urticarias.
- Global Phase 3 trial (EMBARQ-ColdU and SD, NCT07266402) is enrolling, initiated in late 2025.
Financial Impact
High potential commercial value; addresses an underserved market with no approved therapies beyond antihistamines. Phase 3 advancement increases probability of regulatory approval and future revenue generation.
Risk Factors
- Phase 3 trial may not replicate Phase 2 results.
- Regulatory approval not guaranteed despite promising data.
- Competition could emerge if other mast cell or biologic therapies advance in urticaria.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $32.07 (+0.16%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $32.07 (−0.16%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $32.07 (+2.23%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access